Table 1.

Patient and disease characteristics, separately for those patients with sarcomatoid histology and UC, NOS. Results are presented as median (quartiles) and frequency (%)

Characteristic	UC, NOS n = 1,722	Sarcomatoid histology n = 131	P
Age at surgery, years	68 (61–75)	68 (58–75)	0.5
Male	1,370 (80%)	93 (71%)	0.027
Neoadjuvant chemotherapy	313 (18%)	38 (29%)*	0.003
Gemcitabine-cisplatin	274 (88%)	29 (76%)
MVAC	13 (4%)	3 (8%)
Other cisplatin-based regimen	3 (1%)	3 (8%)
Carboplatin-based regimen	23 (7%)	2 (5%)
Unknown	0	1 (3%)
Neoadjuvant chemotherapy cycles			0.3
≤3	54 (17%)	3 (8%)
4	212 (68%)	25 (66%)
≥5	30 (10%)	4 (11%)
Unknown	17 (5%)	6 (16%)
Adjuvant chemotherapy	126 (7.3%)	9 (7.0%)	>0.9
Muscle-invasive bladder cancer**	980 (59%)	85 (65%)	0.2
Consensus T stage			<0.001***
pTa	41 (2.4%)	0 (0%)
pTis	108 (6.3%)	0 (0%)
pT1	499 (29%)	8 (6.1%)
pT2	548 (32%)	39 (30%)
pT3	323 (19%)	64 (49%)
pT4	203 (12%)	20 (15%)
Lymph node involvement	273 (17%)	26 (21%)	0.2
Positive margins	63 (3.7%)	7 (5.3%)	0.3
Timing of sarcomatoid histology
On TUR		35 (27%)
At cystectomy		51 (39%)
Both TUR and cystectomy		45 (34%)

^*This includes 25 patients with sarcomatoid differentiation identified at TUR and 13 patients who sarcomatoid differentiation identified only in the cystectomy specimen

^**Clinical stage at time of treatment.

^***For consensus T stage, the data are presented for all stages, but when comparing consensus T stage between patients with and without sarcomatoid histology, the pTa, pTis and pT1 groups were combined, and a chi-squared test was used.